PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib Case Study PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…Jim Gallagher2021 年 8 月 12 日
Succeeding in Value Communication: Introduction Blog 价值沟通制胜之道:导言 Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…Certara2021 年 8 月 5 日
DDI Regulatory Poster Child using the Simcyp Simulator: Ibrutinib (Imbruvica®) Case Study 使用 Simcyp Simulator 的 DDI 监管典范案例:Ibrutinib (Imbruvica®) Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…Jim Gallagher2021 年 7 月 29 日
What is BaseCase? 视频 What is BaseCase? Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…Certara2021 年 7 月 20 日
Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies Case Study 治疗镰状细胞病的 Voxelotor:无需任何临床研究,利用剂量预测模型进行 DDI 预测 In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…Jim Gallagher2021 年 7 月 14 日
Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers Blog Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…Certara2021 年 6 月 18 日
Three Pathways have emerged in Innovative Access Agreements On-Demand Webinar Three Pathways have emerged in Innovative Access Agreements The days of simply determining the market demand for a new drug as a function…Jim Gallagher2021 年 6 月 11 日
Outcomes Based Agreements On-Demand Webinar Outcomes Based Agreements The days of simply determining the market demand for a new drug as a function…Jim Gallagher2021 年 6 月 11 日
Stakeholder perspectives: current and potential benefits On-Demand Webinar Stakeholder perspectives: current and potential benefits Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…Jim Gallagher2021 年 5 月 26 日
Strengths and opportunities for HTAs and market access in Europe through case studies On-Demand Webinar 通过案例研究了解欧洲 HTA 和市场准入的优势和机遇 Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…Jim Gallagher2021 年 5 月 26 日